SCHEMBL20320548

SCHEMBL20320548

Cc1cc(C(C)(C)C#N)no1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 8/20 0.38
CNR1 P21554 3/20 0.36
TRPM8 Q7Z2W7 1/20 0.34
CHRM2 P08172 1/20 0.32
CHRM4 P08173 1/20 0.32
CHRM5 P08912 1/20 0.32
CHRM3 P20309 1/20 0.32
NPC1 O15118 2/20 0.31
RAB9A P51151 2/20 0.31
ALDH1A1 P00352 2/20 0.31
KDM4E B2RXH2 1/20 0.31
MBOAT4 Q96T53 1/20 0.31
MAPT P10636 2/20 0.31
TP53 P04637 1/20 0.31
TSHR P16473 1/20 0.31
HSD17B10 Q99714 1/20 0.31
CYP2C9 P11712 1/20 0.30
POLB P06746 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1012771 0.78 CNR2 (0.37) CNR2CNR1ALDH1A1KDM4EMBOAT4
SCHEMBL23966685 0.78 MEN1 (0.41) CNR2CNR1NPC1RAB9A
SCHEMBL25799445 0.77 CNR2 (0.39) CNR2CNR1NPC1RAB9AALDH1A1
SCHEMBL427051 0.76 ALDH1A1 (0.43) TRPM8NPC1RAB9AALDH1A1KDM4E
SCHEMBL25796919 0.73 CNR2 (0.36) CNR2CNR1
SCHEMBL1089518 0.72 TRPM8 (0.38) CNR2CNR1TRPM8NPC1RAB9A
SCHEMBL10104245 0.72 TRPM8 (0.38) CNR2TRPM8NPC1RAB9AALDH1A1
SCHEMBL20320491 0.72 TRPM8 (0.38) CNR2TRPM8CHRM2CHRM4CHRM5
SCHEMBL3753522 0.72 RAB9A (0.47) NPC1RAB9AALDH1A1MAPT
SCHEMBL8130541 0.70 ALDH1A1 (0.44) TRPM8NPC1RAB9AALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026099466-A1 TARGETED PROTEIN DEGRADATION MONTE ROSA THERAPEUTICS AG (CH) 2026-05-15 WO disclosed
WO-2021252488-A1 INHIBITORS OF NEK7 KINASE Halia Therapeutics, Inc. (US) 2021-12-16 WO disclosed
WO-2021242505-A1 INHIBITORS OF NEK7 KINASE Halia Therapeutics, Inc. (US) 2021-12-02 WO disclosed
US-20200390100-A1 SUBSTITUTED N-HETEROCYCLYL- AND N-HETEROARYL-TETRAHYDROPYRIMIDINONES AND THE SALTS THEREOF, AND THE USE OF SAME AS HERBICIDAL ACTIVE SUBSTANCES BAYER AG (DE) 2020-12-17 US disclosed
WO-2018114596-A1 SUBSTITUTED HETEROARYL PYRROLONES AND SALTS THEREOF AND USE THEREOF AS HERBICIDAL ACTIVE SUBSTANCES BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) 2018-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200390100-A1 SUBSTITUTED N-HETEROCYCLYL- AND N-HETEROARYL-TETRAHYDROPYRIMIDINONES AND THE SALTS THEREOF, AND THE USE OF SAME AS HERBICIDAL ACTIVE SUBSTANCES DDT, NOTUM, AGPS CNR2 933/4885CNR1 962/4885TRPM8 4135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.